SCHEMBL2168247

SCHEMBL2168247

CCCCNCCCNCCCC

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.73
ALDH1A1 P00352 1/20 0.73
CYP2C19 P33261 2/20 0.62
MEN1 O00255 1/20 0.62
GLA P06280 1/20 0.62
KMT2A Q03164 1/20 0.62
CYP1A2 P05177 1/20 0.59
ADH1B P00325 2/20 0.50
ADH1C P00326 2/20 0.50
ADH1A P07327 2/20 0.50
ADH7 P40394 2/20 0.50
CA12 O43570 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA9 Q16790 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27481446 1.00 TSHR (0.73) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL10045094 1.00 TSHR (0.73) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL5323389 1.00 TSHR (0.73) TSHRALDH1A1CYP2C19MEN1GLA
Hydrochloric Acid SCHEMBL8024908 0.96 TSHR (0.69) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL14782578 0.96 TSHR (0.69) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL2532 0.96
SCHEMBL27946380 0.96 TSHR (0.79) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL8010480 0.93 TSHR (0.75) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL16926434 0.93 TSHR (0.87) TSHRALDH1A1CYP2C19MEN1GLA
SCHEMBL6733972 0.93 TSHR (0.65) TSHRALDH1A1CYP2C19MEN1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11344866-B2 Method for activating hydrotreating catalysts ARKEMA FRANCE (FR) 2022-05-31 US claimed
US-20170120230-A1 METHOD FOR ACTIVATING HYDROTREATING CATALYSTS ARKEMA FRANCE (FR) 2017-05-04 US claimed
EP-3157677-A1 METHOD FOR ACTIVATING HYDROTREATING CATALYSTS Arkema France (FR) 2017-04-26 EP claimed
EP-1370563-B1 MESOPOROUS ORGANIC-INORGANIC HYBRID MATERIALS FOR SEPARATING GASES CENTRE NAT RECH SCIENT (FR) 2006-09-06 EP claimed
EP-1370563-A1 MESOPOROUS ORGANIC-INORGANIC HYBRID MATERIALS FOR SEPARATING GASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2003-12-17 EP claimed
WO-2002076991-A1 MESOPOROUS ORGANIC-INORGANIC HYBRID MATERIALS FOR SEPARATING GASES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2002-10-03 WO claimed
US-12624265-B2 Antistatic agent, antistatic composition comprising same, antistatic resin composition comprising same, and molded article thereof ADEKA CORPORATION (JP) 2026-05-12 US disclosed
US-20250343042-A1 DIFFUSING AGENT COMPOSITION, AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE TOKYO OHKA KOGYO CO LTD (JP) 2025-11-06 US disclosed
US-20250163281-A1 THERMOPLASTIC RESIN COMPOSITION FOR FUSED DEPOSITION MODELING, MODELED BODY, AND METHOD FOR PRODUCING SAME ADEKA CORPORATION (JP) 2025-05-22 US disclosed
EP-4484465-A1 THERMOPLASTIC RESIN COMPOSITION FOR FUSED DEPOSITION MODELING, MODELED BODY, AND METHOD FOR PRODUCING SAME ADEKA CORPORATION (JP) 2025-01-01 EP disclosed
US-20240216290-A1 LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF RECODE THERAPEUTICS, INC. 2024-07-04 US disclosed
WO-2023238799-A1 DIFFUSING AGENT COMPOSITION, AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE 東京応化工業株式会社 2023-12-14 WO disclosed
US-11773287-B2 Method for forming coating TOKYO OHKA KOGYO CO., LTD. (JP) 2023-10-03 US disclosed
US-5153208-A Influence metabolism of collagen or biosynthesis of c/q/ HOECHST AKTIENGESELLSCHAFT (DE) 1992-10-06 US disclosed
US-5037839-A Hydroxylase enzyme inhibitors, influencing the metabolism of collagen and biosynthesis of c1q HOECHST AKTIENGESELLSCHAFT (DE) 1991-08-06 US disclosed
US-4918186-A Process for producing cyclic ureas MITSUI TOATSU CHEMICALS, INC. (JP) 1990-04-17 US disclosed
US-4900820-A REACTING UREA WITH ACYCLIC DIAMINE MITSUI TOATSU CHEMICALS, INC. (JP) 1990-02-13 US disclosed
EP-0249136-A2 Process for producing cyclic ureas MITSUI TOATSU CHEMICALS, Inc. (JP) 1987-12-16 EP disclosed
EP-0248220-A2 Process for producing cyclic ureas MITSUI TOATSU CHEMICALS, Inc. (JP) 1987-12-09 EP disclosed
US-4179469-A Preparation of amines UOP INC. (US) 1979-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624265-B2 Antistatic agent, antistatic composition comprising same, antistatic resin composition comprising same, and molded article thereof SORD, SUCLA2, SUCLG1 TSHR 4867/4885ALDH1A1 196/4885CYP2C19 4010/4885
US-20240216290-A1 LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF LIPA, NPC1L1, NPC1 TSHR 3323/4885ALDH1A1 3082/4885CYP2C19 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.